对肝功能严重受损的转移性乳腺癌患者使用曲妥珠单抗德鲁司坦

IF 0.2 Q4 ONCOLOGY Current problems in cancer. Case reports Pub Date : 2024-11-22 DOI:10.1016/j.cpccr.2024.100337

Laura Sun , Gaybrielle Moore , Annalise Labatut , Jane Meisel , Kevin Kalinsky , Kristina Byers

{"title":"对肝功能严重受损的转移性乳腺癌患者使用曲妥珠单抗德鲁司坦","authors":"Laura Sun , Gaybrielle Moore , Annalise Labatut , Jane Meisel , Kevin Kalinsky , Kristina Byers","doi":"10.1016/j.cpccr.2024.100337","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Trastuzumab deruxtecan (T-DXd) shows efficacy in HER2-positive and HER2-low metastatic breast cancer (MBC), but its safety in patients with hepatic impairment is unclear.</div></div><div><h3>Methods</h3><div>We report three cases of MBC patients with significant liver dysfunction treated with dose-reduced T-DXd after multiple prior therapies.</div></div><div><h3>Results</h3><div>Dose-reduced T-DXd led to improved bilirubin levels and tumor response, with two patients achieving durable responses and enhanced quality of life. Supportive care and tailored dosing were crucial in managing hepatotoxicity.</div></div><div><h3>Conclusion</h3><div>Dose-reduced T-DXd may offer clinical benefit for MBC patients with liver impairment. Further studies are warranted to refine dosing strategies in this population.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"16 ","pages":"Article 100337"},"PeriodicalIF":0.2000,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Administration of trastuzumab deruxtecan in metastatic breast cancer patients with severe hepatic impairment\",\"authors\":\"Laura Sun , Gaybrielle Moore , Annalise Labatut , Jane Meisel , Kevin Kalinsky , Kristina Byers\",\"doi\":\"10.1016/j.cpccr.2024.100337\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Trastuzumab deruxtecan (T-DXd) shows efficacy in HER2-positive and HER2-low metastatic breast cancer (MBC), but its safety in patients with hepatic impairment is unclear.</div></div><div><h3>Methods</h3><div>We report three cases of MBC patients with significant liver dysfunction treated with dose-reduced T-DXd after multiple prior therapies.</div></div><div><h3>Results</h3><div>Dose-reduced T-DXd led to improved bilirubin levels and tumor response, with two patients achieving durable responses and enhanced quality of life. Supportive care and tailored dosing were crucial in managing hepatotoxicity.</div></div><div><h3>Conclusion</h3><div>Dose-reduced T-DXd may offer clinical benefit for MBC patients with liver impairment. Further studies are warranted to refine dosing strategies in this population.</div></div>\",\"PeriodicalId\":72741,\"journal\":{\"name\":\"Current problems in cancer. Case reports\",\"volume\":\"16 \",\"pages\":\"Article 100337\"},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2024-11-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current problems in cancer. Case reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666621924000590\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current problems in cancer. Case reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666621924000590","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景Trastuzumab deruxtecan (T-DXd)对HER2阳性和HER2低下的转移性乳腺癌（MBC）具有疗效，但其对肝功能受损患者的安全性尚不明确。结论降低剂量的T-DXd可为肝功能受损的MBC患者带来临床益处。结论减少剂量的 T-DXd 可为肝功能受损的 MBC 患者带来临床益处，但仍需进一步研究，以完善该人群的用药策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Administration of trastuzumab deruxtecan in metastatic breast cancer patients with severe hepatic impairment

Background

Trastuzumab deruxtecan (T-DXd) shows efficacy in HER2-positive and HER2-low metastatic breast cancer (MBC), but its safety in patients with hepatic impairment is unclear.

Methods

We report three cases of MBC patients with significant liver dysfunction treated with dose-reduced T-DXd after multiple prior therapies.

Results

Dose-reduced T-DXd led to improved bilirubin levels and tumor response, with two patients achieving durable responses and enhanced quality of life. Supportive care and tailored dosing were crucial in managing hepatotoxicity.

Conclusion

Dose-reduced T-DXd may offer clinical benefit for MBC patients with liver impairment. Further studies are warranted to refine dosing strategies in this population.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊